Event
EFMC-ISMC 2026: Meet Axxam in Basel
Katherina Orellana
Head
BD South Europe & Strategic Accounts
Iolanda Micco
Scientific Officer
Integrated Discovery
Meet our Team in Basel
The 29th EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2026) will bring together medicinal chemists, biologists, pharmacologists, and drug discovery experts from around the world to discuss the latest scientific advances driving the development of new therapeutics.
From 6–10 September 2026, Axxam will be in Basel, Switzerland, to meet researchers looking to accelerate their discovery programs through integrated drug discovery solutions. If you are attending EFMC-ISMC, we invite you to connect with our team to discuss how our multidisciplinary expertise can support your next project.
Supporting Medicinal Chemistry with Integrated Biology
Medicinal chemistry is central to the discovery of new medicines, but identifying and optimizing promising compounds requires much more than chemical design. The ability to generate robust biological data early in the discovery process has become essential for understanding target engagement, compound activity, selectivity, and mechanism of action.
At Axxam, we work alongside medicinal chemists by providing the experimental biology that supports informed decision-making throughout hit discovery, hit-to-lead, and lead optimization. Our integrated approach combines assay development, high-throughput screening, advanced cellular models, and translational pharmacology to generate reliable data that guides compound optimization and reduces project risk.
Bridging Biology and Medicinal Chemistry
One of the major themes shaping modern medicinal chemistry is the growing integration of computational approaches, AI-driven target identification, innovative screening technologies, and disease-relevant biological models.
Axxam contributes to this integrated discovery landscape by combining expertise in biology, pharmacology, medicinal chemistry, and data generation within a single collaborative workflow. Whether validating novel targets, characterizing chemical series, or supporting lead optimization, our multidisciplinary teams help transform scientific hypotheses into experimentally validated drug discovery programs.
Our integrated drug discovery model enables seamless collaboration between scientists working across target validation, assay development, screening, medicinal chemistry, and translational biology, helping researchers progress from biological insight to high-quality lead candidates.
Let's Meet at EFMC-ISMC 2026
EFMC-ISMC provides an ideal opportunity to exchange ideas on the scientific challenges currently shaping medicinal chemistry and early drug discovery.
Our team will be available throughout the conference to discuss topics such as AI-enabled drug discovery, target validation, assay development, hit identification, lead optimization, phenotypic screening, and advanced cellular models. Whether your project is at the earliest stages of discovery or progressing toward lead optimization, we would be pleased to explore how Axxam can support your research goals.